6141 related articles for article (PubMed ID: 12530072)
21. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
[TBL] [Abstract][Full Text] [Related]
22. Anti-metastatic efficacy and safety of MMI-166, a selective matrix metalloproteinase inhibitor.
Maekawa R; Maki H; Wada T; Yoshida H; Nishida-Nishimoto K; Okamoto H; Matsumoto Y; Tsuzuki H; Yoshioka T
Clin Exp Metastasis; 2000; 18(1):61-6. PubMed ID: 11206840
[TBL] [Abstract][Full Text] [Related]
23. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.
Koutcher JA; Motwani M; Zakian KL; Li XK; Matei C; Dyke JP; Ballon D; Yoo HH; Schwartz GK
Clin Cancer Res; 2000 Apr; 6(4):1498-507. PubMed ID: 10778982
[TBL] [Abstract][Full Text] [Related]
24. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Herbst RS; Hammond LA; Carbone DP; Tran HT; Holroyd KJ; Desai A; Williams JI; Bekele BN; Hait H; Allgood V; Solomon S; Schiller JH
Clin Cancer Res; 2003 Sep; 9(11):4108-15. PubMed ID: 14519633
[TBL] [Abstract][Full Text] [Related]
25. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
[TBL] [Abstract][Full Text] [Related]
26. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models.
Herbst RS; Takeuchi H; Teicher BA
Cancer Chemother Pharmacol; 1998; 41(6):497-504. PubMed ID: 9554595
[TBL] [Abstract][Full Text] [Related]
27. Acute in vivo resistance in high-dose therapy.
Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor.
Chirivi RG; Garofalo A; Crimmin MJ; Bawden LJ; Stoppacciaro A; Brown PD; Giavazzi R
Int J Cancer; 1994 Aug; 58(3):460-4. PubMed ID: 8050828
[TBL] [Abstract][Full Text] [Related]
29. Quinacrine in endometrial cancer: Repurposing an old antimalarial drug.
Kalogera E; Roy D; Khurana A; Mondal S; Weaver AL; He X; Dowdy SC; Shridhar V
Gynecol Oncol; 2017 Jul; 146(1):187-195. PubMed ID: 28545688
[TBL] [Abstract][Full Text] [Related]
30. Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects on tumor neovascularization.
Schiller JH; Bittner G
Clin Cancer Res; 1999 Dec; 5(12):4287-94. PubMed ID: 10632372
[TBL] [Abstract][Full Text] [Related]
31. Alpha-melanocyte-stimulating hormone blocks invasion of reconstituted basement membrane (Matrigel) by murine B16 melanoma cells.
Murata J; Ayukawa K; Ogasawara M; Fujii H; Saiki I
Invasion Metastasis; 1997; 17(2):82-93. PubMed ID: 9561027
[TBL] [Abstract][Full Text] [Related]
32. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
Ma C; Mandrekar SJ; Alberts SR; Croghan GA; Jatoi A; Reid JM; Hanson LJ; Bruzek L; Tan AD; Pitot HC; Erlichman C; Wright JJ; Adjei AA
Cancer Chemother Pharmacol; 2007 Feb; 59(2):207-15. PubMed ID: 16763792
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activity of Ru(III) complexes carrying beta-diketonato ligands in vitro and in vivo.
Arandjelovic SS; Bjelogrlic KS; Malesevic NN; Tesic LjZ; Radulovic SS
J BUON; 2009; 14(2):271-9. PubMed ID: 19650178
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosan sulfates from E. coli K5 polysaccharide.
Poggi A; Rossi C; Casella N; Bruno C; Sturiale L; Dossi C; Naggi A
Semin Thromb Hemost; 2002 Aug; 28(4):383-92. PubMed ID: 12244486
[TBL] [Abstract][Full Text] [Related]
35. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells.
Chen Z; Koeneman KS; Corey DR
Cancer Res; 2003 Sep; 63(18):5917-25. PubMed ID: 14522918
[TBL] [Abstract][Full Text] [Related]
36. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
[TBL] [Abstract][Full Text] [Related]
37. Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
Zheng X; Chang RL; Cui XX; Avila GE; Hebbar V; Garzotto M; Shih WJ; Lin Y; Lu SE; Rabson AB; Kong AN; Conney AH
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3444-51. PubMed ID: 16740769
[TBL] [Abstract][Full Text] [Related]
38. Antitumor effect of a new selective matrix metalloproteinase inhibitor, MMI-166, on experimental pancreatic cancer.
Matsushita A; Onda M; Uchida E; Maekawa R; Yoshioka T
Int J Cancer; 2001 May; 92(3):434-40. PubMed ID: 11291083
[TBL] [Abstract][Full Text] [Related]
39. PTD4-apoptin protein and dacarbazine show a synergistic antitumor effect on B16-F1 melanoma in vitro and in vivo.
Jin JL; Gong J; Yin TJ; Lu YJ; Xia JJ; Xie YY; Di Y; He L; Guo JL; Sun J; Noteborn MH; Qu S
Eur J Pharmacol; 2011 Mar; 654(1):17-25. PubMed ID: 21184754
[TBL] [Abstract][Full Text] [Related]
40. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
Aissat N; Le Tourneau C; Ghoul A; Serova M; Bieche I; Lokiec F; Raymond E; Faivre S
Cancer Chemother Pharmacol; 2008 Jul; 62(2):305-13. PubMed ID: 17912526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
